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163* Colistin sulfate/tobramycin combination is superior for killing
bioﬁlm P. aeruginosa than monotherapy in vitro
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Here we investigated the efﬁcacy of different antibiotics to kill P. aeruginosa
in bioﬁlms. Strain PAO1 was grown in the Calgary device to 8.9×107 CFU.
At MICs, colistin sulfate, colistimethat, tobramycin or colistin sulfate/tobramycin
reduced bacterial numbers to 6.5×104, 1.1×105, 1.2×105 and 3.5×104 CFUs/ml,
respectively. At 2×MICs numbers were reduced to 3.9×104, 4.6×104, 7.0×104
and 4.0×102 CFU/ml, respectively. In ﬂow cells 4-day-old GFP-labeled PAO1
bioﬁlms were incubated for 24 and 48 h without and with addition of 10×MICs of
colistin sulfate, tobramycin or colistin sulfate/tobramycin to the medium, and the
bacterial killing rate was determined using propidium iodide and the COMSTAT
software. Addition of colistin sulfate, tobramycin or colistin sulfate/tobramycin
killed 84.2%, 8.4% and 99.5% of P. aeruginosa after 24 h, and 77.9%, 35.5%
and 98.8% after 48 h, respectively. Three-dimensional ﬂuorescence imaging of the
P. aeruginosa bioﬁlm incubated with the various antibiotics allowed localization
of dead and surviving bacteria in the ‘mushroom’ structures: while colistin sulfate
killed predominantly the stalk population, tobramycin killed the cap population. The
colistin sulfate/tobramycin combination killed both populations equally. Thus, col-
istin sulfate and tobramycin allow efﬁcient killing of P. aeruginosa and suggest that
simultaneous combination therapy in CF patients is more efﬁcient than alternative
single antibiotic therapy with these drugs to combat lung disease in CF.
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164* Resistance in cystic ﬁbrosis Pseudomonas aeruginosa strains
is not mediated by common acquired antibiotic resistance genes
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Objectives: Beta-lactamases (BL) and aminoglycoside-modifying enzymes (AME)
are important acquired ABR mechanisms in P. aeruginosa. This study analyzes the
relation between the presence of ‘Antibiotic Resistance Genes’ (ARGs) and the
ABR phenotype in CF and non-CF strains.
Methods: 328 unrelated P. aeruginosa clinical CF (43), non-CF (142), animal
(63) and environmental (55) strains, collected in 69 localities on 5 continents and
characterised by, amongst others, FAFLP ﬁngerprinting were PCR-screened for
the presence of 23 ARGs (15 coding for BLs, 8 for AMEs). MIC values for 21
antibiotics were determined by the VITEK 2 Advanced Expert System. The oprD
gene was screened for ‘defective oprD mutations’ (DOMs) that confer carbapenem
resistance.
Results: Fifty-eight ARGs were detected in clinical non-CF isolates. Surprisingly,
CF isolates exhibited no ARGs at all, whilst showing a considerable level of ABR.
Efﬂux pumps and bioﬁlms cause broad spectrum ABR and are more common in
CF isolates. Most of the clinical non-CF strains showed either a moderate or a very
high ARG mediated ABR. 21 distinct DOMs mediated resistance to MER in 22
clinical strains, including 7 CF strains. There was a satisfactory correlation between
ARG detection and the ABR phenotype.
Conclusion: The detection of ARGs through PCR has potential to generate timely
but partial information regarding ABR in non-CF P. aeruginosa strains.
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Objectives: to describe the resistance mechanisms and the epidemiology of
P. aeruginosa strains isolated from CF patients in France.
Methods: 204 P. aeruginosa strains were collected in 10 French hospitals in
2007 (GERPA study group). Their susceptibility (MICs) to 14 antipseudomonal
antibiotics was determined by the standard broth microdilution method. Resistance
mechanisms to b-lactams were assessed phenotypically, by isoelectrofocusing,
PCR, and gene sequencing. The enzymatic activities of b-lactamase AmpC were
measured. The expression levels of efﬂux pumps MexAB-OprM and MexXY/OprM
and of OprD porin were quantiﬁed by real-time RT-PCR. The strains were genotyped
by MLVA using 15 Variable Number Tandem Repeat markers.
Results: According to the EUCAST breakpoints, 76 strains were found to be
resistant to at least one of the 9 b-lactams tested. Analysis of 67 isolates with
ticarcillin MICs >16mg/L showed that 43/67 possessed at least 3 mechanisms
involved in b-lactam resistance. The most frequent phenotype combined AmpC +
overproduction of efﬂux pumps + loss of porin OprD. Rates of efﬂux overproducing
mutants (57/67) were close to that reported for non-CF strains. Reminiscent of
the situation prevailing in non-CF strains, 11/67 of our isolates were found to
harbor acquired b-lactamases, namely VIM (n = 1), TEM-2 (1), PSE-1 (1) and OXA
derivatives (8).
Conclusion: The resistance of CF P. aeruginosa to b-lactams mainly results from
chromosomally mediated resistance mechanisms emerging in individual strains
submitted to repeated courses of chemotherapy.
Supported by: Wyeth.
166 MRSA and macrolide resistant Staphylococcus aureus
colonization rates in a Turkish CF center
O. Dogan1, B. Sener1, E. Yalcin2, D. Dogru2, U. Ozcelik2, N. Kiper2. 1Clinical
Microbiology, Hacettepe University, Ankara, Turkey; 2Pediatric Pulmonology,
Hacettepe University, Ankara, Turkey
Introduction: Increasing prevalence of MRSA and macrolide resistant S.aureus in
CF patients is an emerging problem. This study is aimed to determine the rate of
MRSA and macrolide resistant S.aureus colonization in our CF patients over time.
Methods: A cross-sectional microbiological evaluation of S.aureus isolated from CF
patients attending our center between 01/2005−12/2008 was undertaken. Antibiotic
susceptibilities were determined by CLSI disk diffusion method. The prevalence of
MRSA, multiresistant MRSA and macrolide resistant S.aureus were determined.
Results: The rate of S.aureus isolation was 39.4% in 2005, 46.5% in 2006, 57.9% in
2007 and 61.7% in 2008. The prevalence of MRSA and macrolide resistant S.aureus
positive patients were 6.06%, 41.4% in 2005, 6.4%, 30.5% in 2006, 3.2%, 28% in
2007 and 4.9%, 26.9% in 2008, respectively. Among a total of 21 MRSA colonized
patients, 8 (38.1%) were chronically colonized and six of them had also intermittent
MSSA colonization. The remaining 13 MRSA cases were predominantly colonized
with MSSA during their follow-up. Two of the chronically MRSA colonized cases
had died. Among a total of 72 MRSA isolates, 68% were resistant to erythromycin,
72.2% to ciproﬂoxacin, 75% to gentamicin and 6.9 to TMP-SXT. Multidrug resistant
MRSA was detected in 8 patients (38.1%).
Conclusion: Although MRSA colonization of CF patients is limited in our unit,
multidrug resistant MRSA phenotype constitutes a signiﬁcant proportion, thus
necessitating adherence to infection control policies. Macrolide resistance although
exhibiting a decreasing trend overtime, is of considerable importance and could be
attributed to the increased use of macrolides especially in children.
